122 related articles for article (PubMed ID: 16885359)
1. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells.
Młynarczuk-Biały I; Roeckmann H; Kuckelkorn U; Schmidt B; Umbreen S; Gołab J; Ludwig A; Montag C; Wiebusch L; Hagemeier C; Schadendorf D; Kloetzel PM; Seifert U
Cancer Res; 2006 Aug; 66(15):7598-605. PubMed ID: 16885359
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.
Munshi A; Kurland JF; Nishikawa T; Chiao PJ; Andreeff M; Meyn RE
Mol Cancer Ther; 2004 Aug; 3(8):985-92. PubMed ID: 15299081
[TBL] [Abstract][Full Text] [Related]
3. A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells.
Shumway SD; Miyamoto S
Biochem J; 2004 May; 380(Pt 1):173-80. PubMed ID: 14763901
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation.
Han Y; Weinman S; Boldogh I; Walker RK; Brasier AR
J Biol Chem; 1999 Jan; 274(2):787-94. PubMed ID: 9873017
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency.
Helmbach H; Kern MA; Rossmann E; Renz K; Kissel C; Gschwendt B; Schadendorf D
J Invest Dermatol; 2002 Jun; 118(6):923-32. PubMed ID: 12060385
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
[TBL] [Abstract][Full Text] [Related]
7. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition improves fractionated radiation treatment against non-small cell lung cancer: an antioxidant connection.
Grimes KR; Daosukho C; Zhao Y; Meigooni A; St Clair W
Int J Oncol; 2005 Oct; 27(4):1047-52. PubMed ID: 16142322
[TBL] [Abstract][Full Text] [Related]
10. IkappaB/NF-kappaB mediated cisplatin resistance in HeLa cells after low-dose gamma-irradiation is associated with altered SODD expression.
Eichholtz-Wirth H; Sagan D
Apoptosis; 2000 Jun; 5(3):255-63. PubMed ID: 11225847
[TBL] [Abstract][Full Text] [Related]
11. Calpain contributes to silica-induced I kappa B-alpha degradation and nuclear factor-kappa B activation.
Chen F; Lu Y; Kuhn DC; Maki M; Shi X; Sun SC; Demers LM
Arch Biochem Biophys; 1997 Jun; 342(2):383-8. PubMed ID: 9186501
[TBL] [Abstract][Full Text] [Related]
12. NF-kappaB activation is required for cisplatin-induced apoptosis in head and neck squamous carcinoma cells.
Kim SB; Kim JS; Lee JH; Yoon WJ; Lee DS; Ko MS; Kwon BS; Choi DH; Cho HR; Lee BJ; Chung DK; Lee HW; Park JW
FEBS Lett; 2006 Jan; 580(1):311-8. PubMed ID: 16376337
[TBL] [Abstract][Full Text] [Related]
13. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha.
Place RF; Noonan EJ; Giardina C
Biochem Pharmacol; 2005 Aug; 70(3):394-406. PubMed ID: 15950952
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells.
Németh ZH; Wong HR; Odoms K; Deitch EA; Szabó C; Vizi ES; Haskó G
Mol Pharmacol; 2004 Feb; 65(2):342-9. PubMed ID: 14742676
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of IkappaB-alpha and IkappaB-beta proteolysis by calpain inhibitor I blocks nitric oxide synthesis.
Milligan SA; Owens MW; Grisham MB
Arch Biochem Biophys; 1996 Nov; 335(2):388-95. PubMed ID: 8914937
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
19. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome.
Mellgren RL
J Biol Chem; 1997 Nov; 272(47):29899-903. PubMed ID: 9368065
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.
Thomas RK; Sos ML; Zander T; Mani O; Popov A; Berenbrinker D; Smola-Hess S; Schultze JL; Wolf J
Clin Cancer Res; 2005 Nov; 11(22):8186-94. PubMed ID: 16299251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
